Overview

Effectiveness of Intravenous Tranexamic Acid in Primary Cerebral Hemorrhage for Prevention of Hematoma Progression: Protocol for a Randomized, Double Blind Placebo-controlled Trial

Status:
Not yet recruiting

Trial end date:
2022-07-01

Target enrollment:
0

Participant gender:
All

Summary

Intracerebral hemorrhage is increasingly becoming a major burden in the society because of significant morbidity as well as mortality. Hematoma volume at the time of presentation as well as hematoma expansion and re-bleed or ongoing bleed further deteriorates the patient making a poor prognosis, however at present no therapy targets this pathological process. Though clinical studies do report benefit of using tranexamic acid in spontaneous intracerebral hemorrhage by reducing hematoma expansion rate as well as decreasing ongoing bleed, large randomized controlled trials have not shown any convincing advantage owing to various limitations in their design and methods. However, they uniformly did not find any significant side effect with the use of tranexamic acid. The aim of this study is to test the hypothesis that intravenous tranexamic acid is superior to placebo by reducing hematoma expansion when given within 24 h of spontaneous intracerebral hemorrhage.

Phase:

Early Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Kathmandu Medical College and Teaching Hospital

Treatments:

Tranexamic Acid

Criteria

Inclusion Criteria:

1. All patients presenting to the emergency department with symptom of hemorrhagic stroke
within 24 hours from onset of symptom or last seen well.

2. Patient who had a follow up

Exclusion Criteria:

1. Glasgow coma scale <9 after resuscitation (as this can lead to biasness; requires
surgery)

2. Contraindication to tranexamic acid,

3. Hemorrhagic stroke secondary to trauma,

4. Hemorrhage was caused by coagulopathy